Comparison of intravitreal bevacizumab with macular photocoagulation for treatment of diabetic macular edema: A systemic review and meta-analysis

International Journal of Ophthalmology

Volumn 7, Issue 6, 2014, Pages 1048-1055

  Liu, Xiang Dong ^a   Zhou, Xiao Dong ^a   Wang, Zhi ^a   Shen, Hong Jie ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Bevacizumab; Diabetic macular edema; Intravitreal injection; Meta analysis; Photocoagulation

Indexed keywords

EID: 84925449735     PISSN: 22223959     EISSN: 22274898     Source Type: Journal    
DOI: 10.3980/j.issn.2222-3959.2014.06.26     Document Type: Article

References (38)

1. Habib SL, Rojna M. Diabetes and risk of cancer. ISBN Oncol 2013; 2013:583-786.
2. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema. Ophthalmology 1995;102(1):7-16.
3. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology 2008;115(11):1859-1868.
4. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early treatment diabetic retinopathy study report number 1. Arch Ophthalmol 1985;103 (12): 1796-1806.
5. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy: ETDRS report number 9.Ophthalmology 1991;98 5 Suppl:766-785.
6. Shoeibi N, Ahmadieh H, Entezari M, Yaseri M. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema: long-term results of a clinical trial. J Ophthalmic Vis Res 2013;8 (2): 99-106.
7. Stefanini FR, Arevalo JF, Maia M. Bevacizumab for the management of diabetic macular edema. World J Diahetes 2013;4(2): 19-26.
8. Thapa R, Maharjan N, Paudyal G. Intravitreal bevacizumab in macular edema secondary to branch retinal vein occlusion: 12-month results. Clin Ophthalmol 20l2;6:l057-l062.
9. Fortin P, Mintzes B, Innes M. A systematic review of intravitreal bevacizumab for the treatment of diabetic macular edema. CADIW Technol overv 5;2013;3(l):e3203.
10. Marey HM, Ellakwa AF. Intravitreal bevacizumab alone or combined with triamcinolone acetonide as the primary treatment for diabetic macular edema. Clin Opthalmol 2011; ;5:1011-1016.
11. Seo JW, Park IW. Intravitreal bevacizumab for treatment of diabetic macular edema. Koiean J Ophthalmol 2009;23(l):17-22.
12. Lee SJ, Kim ET, Moon YS. Intravitreal bevacizumab alone versus combined with macular photocoagulation in diabetic macular edema. Koman J Ophthalmol 2011;25 (5):299-304.
13. Zhang XL, Chen J, Zhang RJ, Wang WJ, Zhou Q, Qin XY. Intravitreal triamcinolone versus intravitreal bevacizumab for diabetic macular edema: a meta-analysis. Int J OphthalmoI 2013;6(4):546-552.
14. Solaiman KA, Diab MM, Dabour SA. Repeated intravitreal bevacizumab injection with and without macular grid photocoagulation for treatment of diffuse diabetic macular edema. Retina 2013;33(8): 1623-1629.
15. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet toassess drug safety worldwide. Br J Ophthalmol 2006;90(l 1): 1344-1349.
16. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17(1):1-12.
17. Begg CB, Mazumdar M. Operating characteristics of a rank correlation testfor publication bias. Biometiics 1994;50(4): 1088-1101.
18. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. MBJ l997;315(7109):629-634.
19. Faghihi H, Roohipoor R, Mohammadi SF, Hojat-Jalali K, Mirshahi A, Lashay A, Piri N, Faghihi Sh. Intravitreal bevacizumab versus combined bevacizumab-triamcinolone versus macular laser photocoagulation in diabetic macular edema. Eur J OphmalmoI 2008;l8(6):94-948.
20. Solaiman KA, Diab MM, Abo-Elenin M. Intravitreal bevacizumab and/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema. Retina 2010;30(10):1638-1645.
21. Azad R, Sain S, Sharma YR, Mahajan D. Comparison of intravitreal bevacizumab, intravitreal triamcinolone acetonide, and macular grid augmentation in refractory diffuse diabetic macular edema: a prospective, randomized study. OmanJ Ophthalmol 2012;5(3)166-170.
22. Rajendram R, Fraser-Bell S, Kaines, A, Michaelides M, Hamilton RD, Esposti SD, Peto T, Egan C, Bunce C, Leslie RD, Hykin PG. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol 2012;130(8): 972-979.
23. Soheilian M, Garfami KH, Ramezani A, Yaseri M, Peyman GA. Two-year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema.
24. Arevalo JF, Lasave AF, Wu L, Diaz-Llopis M, Gallego-Pinazo R, Alezzandrini AA, Berrocal MH; Pan-American Collaborative Retina Study Group (PACORES). Intravitreal bevacizumab plus grid laser photocoagulation or intravitreal bevacizumab or grid laser photocoagulation for diffuse diabetic macular edema: results of the Pan-american Collaborative Retina Study Group at 24 months. Retina 2013;33 (2): 403-413.
25. Gillies MC, Sutter FK, Simpson JM, Larsson J, Ali H, Zhu M. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 2006;113(9):1533-1538.
26. Garcia Fernandez M, Garcia Alonso A, Fonolla Gil M, Rodriguez Villa S. Intravitreal triamcinolone acetonide use in diffuse persistent diabetic macular edema. Arch Soc Esp Oftalmol 2011;86(10):314-319.
27. Qazi HA. Protocol: effect of intravitreal bevacizumab (avastin) in the treatment of macular edema: A systematic review of randomized controlled trials. J Res Med Sci 2012;17(12):1180-1187.
28. Haritoglou C, Kook D, Neubauer A, Wolf A, Priglinger S, Strauss R, Gandorfer A, Ulbig M, Kampik A. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006;26(9): 999-1005.
29. Bandello F, Lanzetta P, Menchini U. When and how to do a grid laser for diabetic macular edema.Doc Ophthalmal 1999; 97(3-4):415-419.
30. Krohne TU, Eter N, Holz FG, Meyer CH. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmal 2008;146(4):508-512.
31. Kwon SI, Kim YW, Bang YW, Lee JY, Park IW. Comparison of natural course, intravitreal triamcinolone, and intravitreal bevacizumab for treatment of macular edema secondary to branch retinal vein occlusion.J Ocul Pharmacol ther 2013;29(1):5-9.
32. Yilmaz, T, Cordero-Coma M. Use of bevacizumab for macular edema secondary to branch retinal vein occlusion: a systematic review. Graefes Arch Chin Exp Ophthalmal 2012;250(6):787-793.
33. Zhu Q, Ziemssen F, Henke-Fahle S, Tatar 0, Szurman P, Aisenbrey S., Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization. Ophthalmology 2008;115 (10): 1750-1755.
34. Gillies MC. What we don't know about avastin might hurt us. Arch Ophthalmal 2006;124(10):1478-1479.
35. Schlichtenbrede FC, Mittmann W, Rensch F, Vom Hagen F, Jonas JB, Euler T. Toxicity assessment of intravitreal triamcinolone and bevacizumab in an retinal explant mouse model using two-photon microscopy. Invest Ophthalmal vis Sci 2009;50(12):5880-5887.
36. Michaelides M, Fraser-Bell S, Hamilton R, Kaines A, Egan C, Bunce C, Peto T, Hykin P. Macular perfusion determined by fundus fluorescein angiography at the 4-month time point in a prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (Bolt Study): report 1. Retina 2010;30(5):781-786.
37. Stewart MW. Critical appraisal of ranibizumab in the treatment of diabetic macular edema. Clin Ophthalmal 2013;7:1257-1267.
38. Bandello F, De Benedetto U, Knutsson KA, Parodi MB, Cascavilla ML, Iacono P. Ranibizumab in the treatment of patients with visual impairment due to diabetic macular edema. Clin Ophthalmol 2011;5:1303-1308.